Suffolk University is a private, non-sectarian university located in downtown Boston, Massachusetts, and with 9,192 students , it is the eighth largest university in Metro Boston. It was founded as a law school in 1906 and named after its location in Suffolk County, Massachusetts.The university is coeducational and comprises the Suffolk University Law School, the College of Arts & science,and the Sawyer Business School, some of its MBA programs currently rank among the top 50 business programs in the country. It has an international campus in Madrid in addition to the main campus in downtown Boston. Due to its strategic location and well-known law school, many notable scholars, prominent speakers and politicians have visited the university. For example, former U.S. president John F. Kennedy, Supreme Court Justice William Rehnquist, and former U. S. President George H.W. Bush. all have given speeches at Suffolk. Wikipedia.
News Article | May 11, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella, a biotechnology company pioneering transformative amino acid-based therapeutics for a range of severe diseases, announced today that Ivana Magovcevic-Liebisch, Ph.D., J.D., has joined the company as Executive Vice President, Chief Strategy and Corporate Development Officer. She comes to Axcella with nearly two decades of senior management experience and will oversee business strategy and development, as well as all corporate legal activities, including intellectual property and commercial planning efforts. “ Axcella’s drug development approach represents a unique opportunity to unlock the full potential of amino acid therapeutics,” said Dr. Magovcevic-Liebisch. “ I feel privileged to be part of Axcella’s growing team and look forward to building on its promising science and establishing new complementary partnerships.” “ We are thrilled to welcome Ivana to Axcella’s senior leadership team. She brings an exceptional combination of extensive expertise in business development, drug commercialization, intellectual property and corporate strategy, making her a critical addition to our senior leadership team as we move into late-stage development and commercialization,” added Robert Connelly, President and Chief Executive Officer of Axcella. Before joining Axcella, Dr. Magovcevic-Liebisch was Senior Vice President and Head of Global Business Development at Teva Pharmaceutical Industries Ltd., where she led and executed over $5 billion in business development transactions ranging from licensing to the acquisition of drug candidates, commercial products and companies. She previously worked at Dyax Corp. for a dozen years in management roles of increasing scope and responsibility, including Executive Vice President and Chief Operating Officer. While at Dyax, Dr. Magovcevic-Liebisch established the commercial infrastructure of the company’s first FDA-approved drug, Kalbitor®, for treatment of hereditary angioedema attacks. She began her career as Director of Intellectual Property and Patent Counsel at Transkaryotic Therapies, Inc. Dr. Magovcevic-Liebisch is currently a director on the boards of biotech companies Applied Genetic Technologies Corporation (AGTC) and Alivio Therapeutics. She is also a trustee of the Wentworth Institute of Technology and an overseer of the Boston Ballet, Boston Museum of Science and Beth Israel Deaconess Medical Center. She holds a Ph.D. in Genetics from Harvard University and a J.D. in High Technology law from Suffolk University Law School. About Axcella Axcella is pioneering revolutionary amino acid-based therapeutics as powerful signaling molecules with broad mechanisms of action applicable to a range of severe diseases. Amino acids critically and uniquely regulate a wealth of essential disease pathways and biologies. Leveraging its unique platform, Axcella seeks to transform the traditional drug discovery process by significantly accelerating the speed of candidate generation to clinical validation within months. The company has translated its discoveries into compounds that have been tested in multiple clinical studies to date, with lead programs in NAFLD/NASH, intractable epilepsies and atrophic diseases, and a rich pipeline of drugs for rare genetic diseases. Axcella was founded by Flagship VentureLabs and has received financing from Flagship Pioneering, alongside co-investors Fidelity Research & Management Group, Gurnet Point Capital and Nestlé Health Science. Axcella is based in Cambridge, Mass. For more information, visit www.axcellahealth.com.
News Article | May 11, 2017
BOSTON, MA, May 11, 2017-- Family and employment law firm Davis & Davis, P.C. has recently published an insightful blog post discussing the emerging workplace rights of the transgender and LGBT employees. This seasoned team of Boston sexual harassment lawyers has been actively involved in building mass awareness to bring an end to employment discrimination against the LGBT community.Davis & Davis, P.C. continues their relentless efforts to safeguard the LGBT community from workplace discrimination by building public awareness. Over the last one year, this Boston sexual harassment lawyer has been discussing this burning issue via a series of blog posts. The latest post in the firm's blog speaks about some of the recent developments towards the establishment of workplace rights in the LGBT community.The most common form of sexual harassment at the workplace is the unwelcoming conduct by any male towards his female counterpart. However, there are many different combinations of gender-based discrimination including lesbian, gay, bisexual, and transgender discrimination.In their latest blog post, Davis & Davis, P.C. draws the reader's' attention towards Caitlyn Jenner's recent act of identifying herself as a transgender woman. Though this courageous decision grabbed people's attention all over the United States, the article mentions that three out of every five American citizens come from areas that do not have any laws to prohibit employment discrimination on the basis of gender identity and sexual orientation.However, the noted family and employment law firm takes heart from some recent rulings that were brought to protect the workplace rights of LGBT workers. "The Equal Employment Opportunity Commission (EEOC) handed down a historic ruling on employment discrimination on July 16, 2015. The ruling affirmed that under the provisions of Title VII of the Civil Rights Act of 1964, employment discrimination based on sexual orientation is prohibited," the article states.It has also been informed that the Massachusetts Legislature prohibits all types of distinction between straight and LGBT individuals and the state recognizes workplace protection for the transgender individuals. At the end of the blog post, Davis & Davis, P.C. urges the workplace discrimination victims in Boston to contact Attorney John Davis at 978-276-0777.To read the entire article, please visit http://davisanddavispc.com/evolving-workplace-rights-in-the-lgbt-community/ About Davis & Davis, P.C.: Davis & Davis, P.C., is a family and employment law firm in North Reading, Massachusetts, led by the husband-wife team of attorneys John Davis and Patricia Davis. As graduates of Suffolk University Law School in Boston, they bring their Boston roots to the North Shore and through Massachusetts. All of the lawyers at our firm focus on providing clients with sophisticated legal solutions and high-caliber representation.Website: http://davisanddavispc.com/ PR contact:firstname.lastname@example.orgLaw Firm Phone: 978-276-0777
News Article | May 8, 2017
NEW YORK--(BUSINESS WIRE)--FOX News has appointed Marianne Gambelli to President, Advertising Sales, announced Rupert Murdoch, Executive Chairman, 21st Century Fox. Gambelli will oversee advertising sales for both FOX News Channel (FNC) and FOX Business Network (FBN). She will begin her new role on May 22nd. In making the announcement, Murdoch said, “We are delighted to add Marianne to our executive management team. Her reputation for client management, along with her ability to monetize investments, seek out new and emerging technologies and create innovative media partnerships has made her a leader in the industry.” Gambelli added, “I'm proud to be representing the powerful FOX News brand and I am beyond excited to lead a very talented sales team to capitalize on this new era in news." Prior to joining FOX News, Gambelli served as Chief Investment Officer at Horizon Media where she managed their $7 billion investment portfolio. There she was responsible for a team of over 350 general market investment specialists and actively developed key new business acquisitions across top tier brands. She joined the company in 2012 from NBC Universal, where she most recently held the title of President of Sales and Marketing. During her 22 year tenure at NBC, Gambelli oversaw partnerships and strategy across NBC’s News, Sports and Entertainment brands, optimizing their $7 billion in media investments. In 2012, Advertising Age named Gambelli as one of the 100 Most Influential Women in Advertising and in 2002, she was honored as part of the American Advertising Women to Watch. While at NBC Universal, she was a member of GE’s Women’s Network and served as a Division NBC Universal Leader. She was also a Leader in the company’s Commercial Leadership Program. A graduate of Pace University with a Bachelor of Business degree in Marketing, Gambelli began her career on the agency side, working for Grey Advertising and Backer Speilvogel Bates. In 2016, she was awarded an Honorary Degree from Pace Pleasantville Chapter of Beta Gamma Sigma. She is currently a Board Member of the International Radio and Television Society (IRTS) Foundation. FOX News Channel (FNC) is a 24-hour all-encompassing news service dedicated to delivering breaking news as well as political and business news. The number one network in cable, FNC has been the most-watched television news channel for 15 years and according to a Suffolk University/USA Today poll, is the most-trusted television news source in the country. Owned by 21st Century Fox, FNC is available in 90 million homes and dominates the cable news landscape, routinely notching the top ten programs in the genre.
News Article | May 9, 2017
Dr. Clarke counsels clients in strategic patent procurement, IP due diligence, and worldwide prosecution in the area of biotechnology and the life sciences. He works with a broad range of clients – from small biotech start-ups and academic institutions, to mid-sized and large biotechnology and pharmaceutical companies – in the fields of cellular and molecular biology, oncology, immunology, microbiology, and virology, among others. Dr. Clarke earned his B.A. from the University of Texas in 2001, his Ph.D. in molecular microbiology from the University of Texas Southwestern Medical Center in 2006, and his J.D., with distinction, from Suffolk University in 2011. In 2016, he was recognized as a Rising Star by Massachusetts Super Lawyers and as a Future Leader by the Greater Boston Chamber of Commerce. Dr. Cowles possesses law firm and in-house experience in biotechnology patent preparation and prosecution, domestic and international IP portfolio management, and IP due diligence. His areas of expertise include oligonucleotide therapeutics, oncology, diagnostics, antibody, microbiology, virology, cell biology, and genomic technologies. Dr. Cowles earned his B.A., magna cum laude, in biochemistry and economics from Rice University in 1992, his Ph.D. in biomedical sciences from the University of California – San Diego in 1998, and his J.D., cum laude, from Suffolk University in 2008. He performed post-doctoral research at the Whitehead Institute/MIT as a Damon Runyon fellow, and has been recognized as a Rising Star in 2016 by Massachusetts Super Lawyers. Dr. Emmons counsels corporate and institutional clients in the preparation and prosecution of U.S. and foreign patents in the life sciences, medical device, and mechanical art areas. He assists clients with IP due diligence, IP licensing, and patentability, infringement, validity, and freedom-to-operate analyses. His areas of expertise include cell and molecular biology, genetics, and developmental biology. Dr. Emmons earned his B.A. in ecology from the College of the Atlantic in 1992, his Ph.D. in developmental biology from Washington University School of Medicine in 2000, and his J.D. from Suffolk University in 2012. He also performed post-doctoral research in the Department of Genetics at the Harvard Medical School. He has been recognized as a Rising Star (2014-2016) by Massachusetts Super Lawyers. The legal and scientific prowess of Drs. Clarke, Cowles, and Emmons further enhances Burns' existing team of high-caliber IP and business attorneys who advise life sciences companies throughout their life cycle – from technology and product licensing, patent and trademark procurement and enforcement, and strategic partnering and acquisitions to public and private financings, cross-border transactions, and export regulation compliance. The firm represents life sciences companies and entrepreneurs around the globe in diverse industries including biotechnology, clinical diagnostics, health care, medical devices, medical equipment, and pharmaceuticals, as well as academic institutions and research organizations. About Burns & Levinson LLP At Burns & Levinson, we provide high-level, client-centric and results-oriented legal services to our regional, national and international clients. We are a full-service law firm with over 125 lawyers in Boston, Providence and other regional offices. The firm has grown steadily and strategically throughout the years and has become a premier law firm. Our areas of expertise include: business/finance, business litigation/dispute resolution, divorce/family law, venture capital/emerging companies, employment, estate planning, government investigations, intellectual property, M&A/private equity, probate/trust litigation, and real estate. We partner with our clients to solve their business and personal legal issues in a collaborative, creative, and cost-effective way. For more information, visit Burns & Levinson at www.burnslev.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/burns--levinson-expands-intellectual-property-practice-with-addition-of-three-life-sciences-partners-300454214.html
Suvak M.K.,Suffolk University
Journal of consulting and clinical psychology | Year: 2013
We examined 4 separate dimensions of functional social support (tangible, appraisal, self-esteem, and belonging) as predictors of change in depression over 4.5 years in a sample of women reporting intimate partner violence. Participants were recruited as they sought help for violence perpetrated by a current or former male partner. Three hundred eighty-eight participants completed the Interpersonal Support Evaluation List (Cohen, Mermelstein, Kamarck, & Hoberman, 1985), the Conflict Tactics Scale-2 (Straus, Hamby, Boney-McCoy, & Sugarman, 1996), and the Center for Epidemiologic Studies Depression Scale (CES-D; Radloff, 1977) at the baseline assessment. Participants were reevaluated on 9 follow-up assessment occasions over approximately 4.5 years, during which they completed the CES-D. Growth curve analyses revealed that belonging, or the perceived availability of people one can do things with, was the only dimension that predicted changes in depressive symptoms when controlling for initial depressive symptom levels. Higher levels of belonging support reported at the baseline assessment were associated with larger decreases in depression. The findings of the current study suggest that interventions should consider ways to get survivors connected to informal social networks. Neither perceived availability of material aid nor availability of someone to talk about one's problems or serve as a positive comparison when comparing oneself to others was associated with decreased depression over time. Only perceived availability of people one can do things with (i.e., belonging support).
Sultan N.,Suffolk University
International Journal of Information Management | Year: 2014
Cloud or utility computing is an emerging new computing paradigm designed to deliver numerous computing services through networked media such as the Web. This approach offers several advantages to potential users such as "metered" use (i.e., pay-as-you-go) which offers scalability, online delivery of software and virtual hardware services (e.g., collaboration programmes, virtual servers, virtual storage devices) which would enable organizations to obviate the need to own, maintain and update their software and hardware infrastructures. The flexibility of this emerging computing service has opened many possibilities for organizations that did not exist before. Among those organizations are those engaged in healthcare provision. The aim of this article is to shed some light on this development and explore the potential (and future) of cloud computing in contributing to the advancement of healthcare provision. A small case study will also be presented and discussed. © 2014 Elsevier Ltd.
Sultan N.,Suffolk University
International Journal of Information Management | Year: 2013
Organizations, of all types, live in an increasingly dynamic world. Much of this dynamism is generated by developments or innovations in technology, especially information and communication technology (ICT). Some organizations take advantage of this dynamism and create new products and business models and thrive. Others ignore it or take a long time trying to adapt to it and struggle, often with negative consequences. Some of these innovations, to use the terminology of Christensen, are of a "disruptive" nature such as the telephone, the Web and recently cloud computing. This paper explores the innovation phenomenon of cloud computing and Web 2.0 and specifically examines their impact on organizational knowledge. © 2012 Elsevier Ltd.
Agency: NSF | Branch: Continuing grant | Program: | Phase: | Award Amount: 617.75K | Year: 2014
This project is supporting three cohorts of academically talented students with demonstrated financial need in attaining baccalaureate degrees in electrical engineering at Suffolk University. Scholar recruitment is being done in partnership with the Boston Public High School system, with additional support from local power industries. Cohort-building and developmental activities for scholars build on best practices from other institutions and include a project-based first-year seminar, enrichment and career-development sessions, course-affiliated study groups, faculty and peer mentoring, and internship opportunities. The intellectual merit of the project lies in a cohesive and focused approach to scholar recruitment, retention and career transitions which leverages strong participation by high schools and industry and the supportive community of electrical-engineering students and faculty at Suffolk. The broader impacts include expanding and diversifying the power-industry workforce, as well as providing a well-assessed model for consideration by similar institutions.
Agency: NSF | Branch: Standard Grant | Program: | Phase: Genetic Mechanisms | Award Amount: 361.20K | Year: 2016
Bacteria have the remarkable ability to acquire new genes in a process known as conjugation, which plays a profound role in bacterial evolution and adaptation to different environments. During conjugation, DNA is transferred from one cell to another through a specialized translocation channel. Many of the molecular mechanisms behind the conjugation process remain a mystery. This project will characterize two critical interacting protein components of the conjugation machinery of the bacterium Bacillus subtilis, providing insight into how they function, interact, and localize. The research will be designed and conducted by 12 highly qualified and diverse undergraduate students. By attaining this independent, inquiry-driven research experience, students are more likely to remain in science and gain employment or entrance to top-tier graduate programs after graduation. This project will also improve science education by enabling a professor from a diverse community college to do research and learn new techniques.
The subject of this study is a specialized DNA translocation channel known as a Type IV secretion system (T4SS). While the T4SSs found in several Gram-negative bacteria have been well-studied, much less is known about those of Gram-positive bacteria. This project aims to examine the conjugation machinery of Gram-positive bacteria using the integrative and conjugative element ICEBs1 of B. subtilis as a model system. Prior results indicate that the ICEBs1 T4SS is composed of ConE and ConB, among other proteins. ConE is a peripheral membrane ATPase that likely energizes DNA transfer and/or channel assembly. The bitopic membrane protein ConB interacts with ConE and is required for its association with the membrane. ConB and ConE will be characterized by a variety of methods including mutagenesis, conjugation assays, fluorescence microscopy, and biochemistry. This research will define the conserved sequence motifs and domains of ConB and ConE that are required for conjugation, interaction, enzymatic function, and oligomerization. As these proteins are conserved, the findings will apply to the conjugation machinery of numerous Gram-positive bacteria and provide a deeper understanding of a major mechanism mediating horizontal gene transfer.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Knowledge Transfer Partnership | Award Amount: 40.96K | Year: 2016
To explore development of Virtual/Augmented Reality tools for the healthcare education, patient/professional treatment visualization and stimulation. To embed outcomes and efficiencys within primary and acute healthcare provision.